Skip to main content
Delfa

← Trials/Trial dossier/NCT02450253

PASTIS

CompletedPhase 2

Perfusion by Arterial Spin Labelling Following Single Dose Tadalafil in Small Vessel Disease (PASTIS) Trial

Asset

tadalafil

Listed sites

1

Recruiting sites

-

Enrollment

55

actual

Study population

Mixed / unspecified dementia

Key I/E criterion

Age ≥55

Primary endpoint

Deep brain blood flow

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study ID14.0189
Secondary ID15/LO/0714Research Ethics Committee (REC)
Other grant20140901ADDF
Eudract number2015-001235-20
NCT IDNCT02450253

Timeline

Milestones

Study first posted2015-05-21estimated
Study start2015-09 (month precision)
Primary completion2018-01-25actual
Study completion2018-01-25actual
Last update posted2022-10-27actual

Assets

Drug assets

Study populations

Who this study enrolls

Mixed / unspecified dementia

Eligibility

Who can enroll

Minimum age55 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

1. Radiological evidence of cerebral small vessel disease defined as: MRI evidence of lacunar infarct(s) (≤ 1.5 cm maximum diameter) and/or confluent deep white matter leukoaraiosis (≥ grade 2 on Fazekas scale)

2. Clinical evidence of cerebral small vessel disease can be:

1. lacunar stroke syndrome with symptoms lasting >24 hours, occurring at least 6 months previously; OR:

2. transient ischaemic attack lasting < 24 hours with limb weakness, hemi-sensory loss or dysarthria at least 6 months previously AND with MRI DWI performed acutely showing lacunar infarction, OR if MRI is not performed within 10 days of TIA, a lacunar infarction in an anatomically appropriate position is demonstrated on a subsequent MRI

3. Age ≥ 55 years.

4. Imaging of the carotid arteries with Doppler ultrasound, CT angiography or MR angiography in the previous 12 months, demonstrating < 70% stenosis in both internal carotid arteries

Exclusion criteria

1. Known diagnosis of dementia

2. Cortical infarction (>1.5 cm maximum diameter)

3. Systolic BP <90 and/or diastolic BP < 50

4. Creatinine Clearance<50ml/min

5. Severe hepatic impairment

6. History of Lactose intolerance

7. Concomitant use of PDE5 inhibitors e.g. sildenafil, tadalafil, vardenafil.

8. Concomitant use of alpha-blockers e.g. alfuzosin, doxazosin, indoramin, prazosin, tamsulosin, and terazosin can all increase the risk of postural hypotension.

9. Participants receiving nicorandil and nitrates e.g. isosorbide mononitrate, isosorbide dinitrate, glyceryl trinitrate

10. weight > 130kg

11 Uncontrolled cardiac failure

12. Persistent or paroxysmal atrial fibrillation

13. History of gastric ulceration

14. History of 'sick sinus syndrome' or other supraventricular cardiac conduction conditions such as sinoatrial or atrioventricular block

15. Uncontrolled COPD

16. Stroke or TIA within the last 6 months

17. MRI not tolerated or contra-indicated : MRI exclusion criteria -Participant has a cardiac pacemaker; recent surgery; vascular clips; metal implants or joint replacements; have had metal fragments in their eyes; has ever worked on a lathe; has shrapnel from a war injury; possibility of pregnancy

18. Known monogenic causes of stroke e.g.. CADASIL

19 Unable to provide informed consent

20. enrolled in another CTIMP study

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Executive function / language
1
Neuroimaging
1

Executive function / language

1 endpoint
Secondary/protocol endpoint

Change in regional CBF in cortical grey matter areas Plasma [drug concentration] dependence of deep CBF as measured by MRI ASL Changes in neuropsychological parameters including attention in Neuro attention and cognitive speed

Time frame:3-5 hours following IMP dosing

change from baseline, improvement

Neuroimaging

1 endpoint
Primary/protocol endpoint

change in deep brain blood flow as measured by MRI-Arterial Spin Labelling

Time frame:3-5 hours following IMP dosing

change from baseline, improvement

Publications (2)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 21, 2026
Endpoint classificationDelfa ADRD endpoint taxonomy
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.